Literature DB >> 1322190

Epstein-Barr virus infection in allogeneic marrow grafting: lessons for transplant physicians and virologists.

J W Gratama1, M A Oosterveer, J Lepoutre, W E Fibbe, O Ringdén, J M Vossen, R Willemze, R L Bolhuis, J J van Rood, I Ernberg.   

Abstract

The relationship between Epstein-Barr virus (EBV) and the host is profoundly disturbed by allogeneic bone marrow transplantation (BMT) because EBV resides in the recipient's hematopoietic system, which has to be destroyed in the majority of cases, and in the donor's hematopoietic system, i.e., the marrow graft. We have shown that EBV may be eradicated from some BMT recipients and that the virus may be transferred with the marrow graft. During the immediate post-transplant period oropharyngeal EBV excretion may occur which, by infecting passing B lymphocytes, may act as co-factor for acute graft-versus-host disease and help the virus to survive, despite the temporary depletion of its reservoir. The coexistence of totally different EBV strains in BMT recipients but not in healthy, untransfused controls, suggests that superinfection may by possible in case of immunodeficiency; alternatively, transfer of the virus by the reservoir itself (the B lymphocytes) might be the only effective route for superinfection. The generation of 'variant' strains during viral replication may form the basis of the vast polymorphism between wild-type EBV isolates in the population.

Entities:  

Mesh:

Year:  1992        PMID: 1322190     DOI: 10.1007/bf01715373

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

1.  Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients.

Authors:  J W Gratama; M M Zutter; J Minarovits; M A Oosterveer; E D Thomas; G Klein; I Ernberg
Journal:  Int J Cancer       Date:  1991-01-21       Impact factor: 7.396

2.  Serological and molecular studies of Epstein-Barr virus infection in allogeneic marrow graft recipients.

Authors:  J W Gratama; M A Oosterveer; J M Lepoutre; J J van Rood; F E Zwaan; J M Vossen; J G Kapsenberg; D Richel; G Klein; I Ernberg
Journal:  Transplantation       Date:  1990-04       Impact factor: 4.939

3.  Epstein-Barr virus lymphoproliferation after bone marrow transplantation.

Authors:  M M Zutter; P J Martin; G E Sale; H M Shulman; L Fisher; E D Thomas; D M Durnam
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

4.  Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency.

Authors:  J W Gratama; M A Oosterveer; F E Zwaan; J Lepoutre; G Klein; I Ernberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

5.  EBNA size polymorphism can be used to trace Epstein-Barr virus spread within families.

Authors:  J W Gratama; M A Oosterveer; G Klein; I Ernberg
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

6.  Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects.

Authors:  T B Sculley; A Apolloni; L Hurren; D J Moss; D A Cooper
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

7.  Epstein-Barr virus-related serology in marrow transplant recipients.

Authors:  B Lange; W Henle; J D Meyers; L C Yang; C August; P Koch; A Arbeter; G Henle
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

8.  Herpes-virus immunity and acute graft-versus-host disease.

Authors:  J W Gratama; F E Zwaan; T Stijnen; T F Weijers; H T Weiland; J D'Amaro; A C Hekker; T H The; G C de Gast; J M Vossen
Journal:  Lancet       Date:  1987-02-28       Impact factor: 79.321

9.  Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients.

Authors:  J W Gratama; E T Lennette; B Lönnqvist; M A Oosterveer; G Klein; O Ringdén; I Ernberg
Journal:  J Med Virol       Date:  1992-05       Impact factor: 2.327

  9 in total
  2 in total

Review 1.  Viral infections in severely immunocompromised cancer patients.

Authors:  S M Devine; J R Wingard
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

2.  Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection.

Authors:  Shizuko Harada; Yoshio Kamata; Yasuyuki Ishii; Hiroyuki Eda; Ryo Kitamura; Maya Obayashi; Sayuri Ito; Fumihiko Ban; Jun Kuranari; Haruhiko Nakajima; Tomoko Kuze; Masao Hayashi; Nobuhiko Okabe; Hidenobu Senpuku; Nobuyuki Miyasaka; Yoshiko Nakamura; Hirokazu Kanegane; Kazuo Yanagi
Journal:  Clin Diagn Lab Immunol       Date:  2004-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.